Volume 21 - Issue 8 - September, 2009

Craig A. Thompson, MD, MMSc From the Director of Invasive Cardiology and Vascular Medicine and Associate Professor of Medicine, Yale University School of Medicine, New Haven, Connecticut. Disclosure: Dr Thompson is a consultant for Abbott Vascular, Asahi Intec, Bridgepoint Medical, and Medtronic. Address for correspondence: Craig A. Thompson, MD, MMSc, Director of Invasive Cardiology and Vascular, Yale University School of Medicine, PO Box 208017, 333 Cedar Street, New Haven, CT 06520-8017. E-mail: Craig.Thompson@Yale.edu

¹John P. Vavalle, MD; ^1,2Sunil V. Rao, MD From ¹Duke University Medical Center and ²The Duke Clinical Research Institute, both in Durham, North Carolina. Disclosure: Dr. Vavalle reports no conflicts of interest regarding the manuscript content herein. Dr. Rao receives research funding from Cordis Corporation, Momenta Pharmaceuticals, and Portola Pharmaceuticals, and receives honoraria for consulting or speaking for Sanofi-Aventis, Bristol Myers Squibb, and The Medicines Company. Address for correspondence: John P. Vavalle, MD, Duke University Medical Center, Division of Cardiovascular Medicine, Box 31356, Durham, NC 27710-0001. E-mail: jv18@notes.duke.edu

Ronald P. Caputo, MD From St. Joseph’s Hospital, Syracuse, New York. Disclosure The author has disclosed no conflicts of interest regarding the content herein. Address for correspondence: Ronald P. Caputo, MD, FACC, FSCAI, SJH Cardiology Associates, 4820 W. Taft Rd., Liverpool, NY 13088. E-mail: caputo331@msn.com

Mauricio G. Cohen, MD; Carlos Alfonso, MD From the Cardiovascular Division, Miller School of Medicine, University of Miami, Miami, Florida. Disclosure: Dr. Cohen reports no conflicts of interest regarding the content herein. Dr. Alfonso reports no conflicts of interest regarding the content herein. Address for correspondence: Mauricio G. Cohen, MD, FACC, University of Miami Hospital, 1400 N.W. 12th Avenue, Room 1179, Miami, FL 33136. E-mail: mgcohen@med.miami.edu Acknowledgment: The authors acknowledge the excellent editorial assistance of Eric Scot Shaw in the preparation of this manuscript.

Sunil V. Rao, MD From The Duke Clinical Research Institute, in Durham, North Carolina. Disclosure: Dr. Rao receives research funding from Cordis Corporation, Momenta Pharmaceuticals, and Portola Pharmaceuticals, and receives honoraria for consulting or speaking for Sanofi-Aventis, Bristol Myers Squibb, and The Medicines Company. Address for correspondence: Sunil V. Rao, MD, 508 Fulton Street (111A), Durham, NC 27705. E-mail: sunil.rao@duke.edu